Balofloxacin dihydrate  (Synonyms: Q-35 dihydrate)

Balofloxacin dihydrate (Q-35 dihydrate) is an orally active fluoroquinolone antibiotic with broad-spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. Balofloxacin dihydrate can be used for the research of respiratory, intestinal, and urinary tract infections^[1][2].

Balofloxacin (25 mg/mL; 1 h) decreases the growth of S. aureus that adhered to human corneal epithelial cells (HCECs)^[2].
Balofloxacin inhibits the S. aureus ATCC 25923, with a MIC of 0.125 mg/mL^[2].
Balofloxacin (0.05-500 μg/mL; 72 h) does not induce toxicity on the HCECs at a low concentration, such as 0.625 mg/mL^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Balofloxacin (200 mg/kg/day; p.o. for 5 d) reduces the counts of viable M. pneumonia in the lungs of hamsters^[3].
Balofloxacin eye drops (0.5%) is effective in S. aureus bacterial keratitis of rabbits^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

425.45

C₂₀H₂₈FN₃O₆

151060-21-8

巴洛沙星二水合物

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Alksne L. Balofloxacin Choongwae. Curr Opin Investig Drugs. 2003 Feb;4(2):224-9.  [Content Brief]

  [2]. Jiang H, et, al. In vitro and in vivo effectiveness evaluation of balofloxacin in experimental Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2014 Aug;30(6):482-8.  [Content Brief]

  [3]. Gohara Y, et, al. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumonia. Antimicrob Agents Chemother. 1993 Sep;37(9):1826-30.  [Content Brief]